Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer-Reference-Cited by-同舟云学术

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

Published:2010-03-26 Issue:1 Volume:121 Page:121-131
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Barrios Carlos H.,Liu Mei-Ching,Lee Soo Chin,Vanlemmens Laurence,Ferrero Jean-Marc,Tabei Toshio,Pivot Xavier,Iwata Hiroji,Aogi Kenjiro,Lugo-Quintana Roberto,Harbeck Nadia,Brickman Marla J.,Zhang Ke,Kern Kenneth A.,Martin Miguel

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-010-0788-0.pdf

Reference23 articles.

1. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792

2. Blackwell KL, Burstein HJ, Sledge GW et al (2009) Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. In: San Antonio Breast Cancer symposium (Abstract 61)

3. Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F, Piccart MJ (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13(2):197–207

4. Roche Pharmaceuticals (2006) XELODA (capecitabine) prescribing information, Nutley, NJ

5. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4(9):536–550

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel delivery of sorafenib by natural killer cell-derived exosomes-enhanced apoptosis in triple-negative breast cancer;Nanomedicine;2023-02

2. Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future;Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer;2023-01

3. Promalignant effects of antiangiogenics in the tumor microenvironment;Seminars in Cancer Biology;2022-11

4. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease;Cancer Letters;2022-10

5. Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis;Frontiers in Oncology;2022-08-01